Recent Advances in Diagnosis of Foot-and-Mouth Disease
Your SlideShare is downloading.
×
Check these out next
Recommended
More Related Content
Slideshows for you (20)
Similar to OS16 - 4.P2.c Efficacy of a FMD Inactivated Vaccine (Aftovaxpur DOE), Administered at a 1ml Dose to Sheep - C. Hamers (20)
More from EuFMD (20)
Recently uploaded (20)
OS16 - 4.P2.c Efficacy of a FMD Inactivated Vaccine (Aftovaxpur DOE), Administered at a 1ml Dose to Sheep - C. Hamers
- 1. Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers
- 2. Efficacy of a Foot-and-Mouth Disease inactivated vaccine (AFTOVAXPUR DOE), administered at a 1 mL dose to sheep Claude Hamers
- 3. • In field practice, FMD vaccines are frequently administered to sheep at half the dose recommended for cattle • Main reasons for this practice: i) a lower susceptibility of sheep to FMD infection ii) the relative vaccine cost as compared to the value of a sheep • Study to compare vaccination of sheep with an AFTOVAXPUR DOE vaccine ᴑ 1 mL (half dose) ᴑ 2 mL (full dose) Introduction = registered claim
- 4. • Animals : 30 ewes, 1 year olds, Texel breed, randomly allocated to 3 groups in high containment throughout the study • Vaccine : AFTOVAXPUR DOE trivalent, formulated at low antigen content O Manisa, A22 Iraq, SAT2 Sau Study design
- 5. G1 (1 mL vaccinated) G2 (controls) G3 (2 mL vaccinated) Study design
- 6. G1 (1 mL vaccinated) G2 (controls) G3 (2 mL vaccinated) Study design
- 7. G1 (1 mL vaccinated) G3 (2 mL vaccinated) Study design
- 8. G1 (1 mL vaccinated) G3 (2 mL vaccinated) Study design
- 9. Study design Immunisation serum sample Comparisons of G1 and G3 on serological responses 7 days
- 10. Study design Immunisation serum sample 7 days
- 11. Study design Immunisation challenge serum sample clinic + temp. FMD lesions blood for virology FMDv O Manisa
- 12. Results : serology
- 13. Results : serology VNT to FMD A22 Iraq D28 VNT in G1 statistically non inferior to D28 VNT in G3
- 14. Results : serology VNT to FMD SAT2 D28 VNT in G1 statistically non inferior to D28 VNT in G3
- 15. Results : serology VNT to FMD O Manisa D28 VNT in G1 statistically inferior to D28 VNT in G3 G1 & G2
- 16. Results : O1 Manisa challenge Intercurrent Footrot infection during the immunization phase
- 17. Results : O1 Manisa challenge Rectal temperatures
- 18. Results : O1 Manisa challenge General Clinical Signs Controls (G2) • every animal presented polypnea and lameness between D29 and D31 • frequently accompanied or preceded by a reduced feed intake Vaccinates (G1) • none of the vaccinates ever presented any general clinical sign
- 19. non specific feet lesions (footrot suspected) G1 (1 mL Vaccinated) G2 (Controls) G3 (2 mL Vaccinated) Group No feet lesions Typical FMD feet lesions 5 32 Number of sheep with (10 sheep per group) 0 110 6 40 Results : O1 Manisa challenge Feet lesions G3 was not challenged !
- 20. Results : O1 Manisa challenge Viraemia G1 G2 Box-and-Whisker Plot 0 1 2 3 4 5 LogAUCviraemia Group
- 21. Results : O1 Manisa challenge G1 (1 mL vaccinated) G2 (controls)
- 22. Results : O1 Manisa challenge G1 (1 mL vaccinated) G2 (controls)
- 23. The study results demonstrated : • Serological equivalence with a 2 mL dose (A22 Iraq, SAT2 Sau) • Clinical and virological protections against a virulent challenge (O Manisa) . Conclusions
- 24. WBR : A. Dekker, M. Bleijenberg Merial B.V. : B. Van Schaijk, J. Coco-Martin Merial S.A.S.: L. Mouton, M. Besset, M. Curet, S. Goutebroze And Technical Staff from the WBR Animal Facilities and MERIAL R&D Lelystad Laboratories . Acknowledgements
- 25. Thank you
- 26. Thank you
- 27. Thank you
- 28. Thank you
- 29. Thank you
- 30. Thank you
